USP44 Stabilizes MAOB via Deubiquitination to Inhibit Cisplatin Resistance in Lung Adenocarcinoma
Zhi Liang, Hui Zhang, Jinhua Jiang, Chuanchuan Li, Feng Yuan · 2026
Read USP44 Stabilizes MAOB via Deubiquitination to Inhibit Cisplatin Resistance in Lung Adenocarcinoma by Zhi Liang, Hui Zhang, Jinhua Jiang, Chuanchuan Li, Feng Yuan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13195626.txt.
Description
Zhi Liang is first author on a 2026 study of cisplatin resistance in lung adenocarcinoma, a deadly lung cancer where the chemotherapy drug cisplatin is first-line treatment. Resistance limits its use, so the authors mined gene data comparing sensitive and resistant cancer cells to find core targets. One gene, MAOB, emerged at the center.
MAOB levels ran low in resistant cells and tumors, and low levels linked to worse prognosis. Raising MAOB restored drug sensitivity, slowed growth, spread, and invasion, and promoted cell death. A partner protein, USP44, was also reduced in resistant models and normally protects MAOB from disposal by removing its shred-me tags. Restoring USP44 only helped while MAOB was present, defining a targetable axis.
Catalog record
| CREATOR | Zhi Liang, Hui Zhang, Jinhua Jiang, Chuanchuan Li, Feng Yuan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |